Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
25000 participants
INTERVENTIONAL
2020-04-20
2021-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Attenuated Zoster Vaccine, Live
One shot of the vaccine (with live viruses titer \>=4.3 LgPFU per dose)
live attenuated zoster vaccine
subcutaneous injection
Placebo
one shot of placebo with no live virus
placebo
subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
live attenuated zoster vaccine
subcutaneous injection
placebo
subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 02 Able to understand and give informed consent;.
* 03 Able to comply with requirements of all clinical trial protocol for completing the study;
* 04 Axillary temperature ≤37.0 at the time of enrollment;
Exclusion Criteria
* 06 History of vaccination against herpes zoster or varicella ;
* 07 Allergic sensitivity to any of the components (including neomycin) in the study vaccine and a history of severe allergies to other vaccine;
* 08 Premenopausal with positive pregnancy test, pregnant or lactating female, or female planning to become pregnant within 6 months;
* 09 Subjects with congenital history of immunity deficiency (e.g., primary immunoglobulin deficiency, isolated IgA deficiency, etc.) or family history;
* 10 Receipt of immunoglobulins and/or any blood products within the 5 months preceding of study vaccine or planning to receive these products during the study period;
* 11 Immunosuppression resulting from disease,such as immunodeficiency, malignant tumor, HIV infection, organ and bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease caused by low immunity; Receipt of immunosuppressive therapy with corticosteroids (except intermittent topical or inhaled corticosteroids \[\< 800 g/ d Beclomethasone or equivalent\]); Other immunosuppressive/cytotoxic treatments (cancer chemotherapy or organ transplantation);
* 12 Subjects with acute infections (such as mumps, etc.), chronic infections in the acute phase (such as active untreated tuberculosis, etc.) or any advanced immune disease;
* 13 Use of any investigational or non-registered product (drug, biological product or device) other than the study vaccine within 1 month before study vaccination , or planed use during the study period;
* 14 Administration or planned administration of any other immunizations within 1 month before study vaccination or scheduled within the study period after study vaccination.
* 15 Any non-local antiviral active treatment within 1 month prior to vaccination, including but not limited to acyclovir, famciclovir, valacyclovir and ganciclovir;
* 16 Taking certain pharmaceuticals to be like salicylate kind, including aspirin, and diflunisal, or going to take these medicine during the study period.
* 17 history of thrombocytopenia or coagulation disorders that may cause subcutaneous injection contraindications;
* 18 significant diseases or significant underlying diseases (such as pulmonary heart disease, pulmonary edema, hypertension that cannot be effectively controlled with drugs \[systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg\] that may interfere with or hinder the completion of the study, serious liver and kidney diseases, diabetes with concurrent symptoms, etc.);
* 19 Various infectious, suppurative and allergic skin diseases;
* 20 History of psychiatric and neurological disorders (e.g., depression, epilepsy or convulsion);
* 21 Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.(e.g., malleable psoriasis, chronic pain syndrome, cognitive impairment, severe hearing loss, and other conditions that may interfere with study evaluation).
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changchun BCHT Biotechnology Co.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fengcai Zhu, Master
Role: PRINCIPAL_INVESTIGATOR
LocationJiangsu Province Center for Disease Control and Prevention
Zhiping Chen
Role: PRINCIPAL_INVESTIGATOR
Zhejiang Provincial Center for Disease Control and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Province Center for Disease Control and Prevention
Nanjing, Jiangsu, China
Zhejiang Provincial Center for Disease Control and Prevention
Hanzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga MEDS, Canteiro Cruz E. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F20190717
Identifier Type: -
Identifier Source: org_study_id